US2019365778A1PendingUtilityA1

Treprostinil administration by inhalation

70
Assignee: UNITED THERAPEUTICS CORPPriority: May 15, 2006Filed: Aug 9, 2019Published: Dec 5, 2019
Est. expiryMay 15, 2026(expired)· nominal 20-yr term from priority
Inventors:Horst OlschewskiRobert RoscignoLewis J. RubinThomas SchmehlWerner SeegerCarl SterrittRobert Voswinckel
A61P 43/00A61P 9/12A61P 9/00A61P 11/00A61K 9/008A61K 9/0078A61K 31/557A61K 31/192A61K 9/12A61K 9/00
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating pulmonary hypertension comprising administering by inhalation to a human suffering from pulmonary hypertension a therapeutically effective single event dose of a formulation comprising treprostinil or a pharmaceutically acceptable salt thereof with an inhalation device, wherein the therapeutically effective single event dose comprises from 15 micrograms to 90 micrograms of treprostinil or a pharmaceutically acceptable salt thereof delivered in 1 to 3 breaths. 
     
     
         2 . The method of  claim 1 , wherein the inhalation device is a soft mist inhaler. 
     
     
         3 . The method of  claim 1 , wherein the inhalation device is a pulsed ultrasonic nebulizer. 
     
     
         4 . The method of  claim 1 , wherein the inhalation device is a dry powder inhaler. 
     
     
         5 . The method of  claim 1 , wherein the inhalation device is a pressurized metered dose inhaler. 
     
     
         6 . An inhalation device for treating pulmonary hypertension in a human suffering from pulmonary hypertension comprising an inhalation device configured to administer a therapeutically effective single event dose of a formulation comprising treprostinil or a pharmaceutically acceptable salt thereof, wherein the therapeutically effective single event dose comprises from 15 micrograms to 90 micrograms of treprostinil or a pharmaceutically acceptable salt thereof delivered in 1 to 3 breaths. 
     
     
         7 . The inhalation device of  claim 6 , wherein the inhalation device is a soft mist inhaler. 
     
     
         8 . The inhalation device of  claim 6 , wherein the inhalation device is a pulsed ultrasonic nebulizer. 
     
     
         9 . The inhalation device of  claim 6 , wherein the inhalation device is a dry powder inhaler. 
     
     
         10 . The inhalation device of  claim 6 , wherein the inhalation device is a pressurized metered dose inhaler.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.